|
|
楼主 |
发表于 2025-1-9 17:21:59
|
显示全部楼层
还统计少了，华西医院牵头是25项
; ?( Y$ g* {8 \4 p: T01.Risk factors of complications after inguinal lymph node dissection in patients with penile cancer.
& [! E, v8 w+ |1 d; S! E- s02.Tislelizumab in combination with abiraterone/enzalutamide for metastatic castration-resistant prostate cancer with intraductal adenocarcinoma of the prostate after progression on prior androgen receptor pathway inhibitor./ N. A2 t- n5 p$ w+ I
03.Discordance in HER2 expression in primary and recurrent/metastatic lesions of upper tract urothelial carcinoma: A study focusing on temporal heterogeneity.
- n! \* D' K3 n- j04.The impact of neoadjuvant therapy on the formation of tertiary lymphatic structures and the distinct prognosis in prostate cancer.
* M$ a& W4 P, t2 F) R& o05.Phenotypic and genetically predicted leukocyte telomere length and prostate cancer risk: Results from a large-scale longitudinal cohort study.' }3 x7 K' E/ n0 P* T2 n
06.Survival impact of concomitant squamous differentiation in upper tract urothelial carcinoma patients receiving adjuvant chemotherapy.2 Z( P: N% g# R) ]
07.Pathological subclassification of T3 upper tract urothelial carcinoma: Complementary evidence for existing guidelines.
+ Z8 |9 i2 b5 U- v) H: _08.Evaluating the efficacy and safety of pelvic lymph node dissection in high-risk prostate cancer patients undergoing radical prostatectomy: A systematic review and meta-analysis.
* p7 a, a: T8 j$ e3 K+ U09.Safety and efficacy of immune checkpoint inhibitor rechallenge in metastatic fumarate hydratase-deficient renal cell carcinoma: A retrospective study.
9 `; ^4 \3 F( \0 J5 s; t10.Interpretable machine learning for prostate biopsy: Cohort study.
& X( P) |2 j4 p& a, j11.Genomic features of prostate cancer patients with and without ductal adenocarcinoma (DA) based on liquid biopsy.
. b! {) D( Q( k, O- N12.Clinicopathological features and prognosis of MED15-TFE3 rearrangement renal cell carcinoma: An updated report.
: j/ s/ k0 u7 F13.Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02).. d4 y5 e5 F8 P+ ^
14.A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).- D$ @' B/ M, A, ?6 @
15.VORSIN-RCC: Vorolanib plus sintilimab for advanced renal cell carcinoma after failure of prior immune checkpoint inhibitors-based combination therapy. c7 I6 z1 R) q8 O% n
16.Cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) combined with axitinib for the first-line treatment of advanced or metastatic non-clear renal cell carcinoma: A prospective, single-arm, phase Ib/II study.
6 C$ }9 V4 \$ J& f17.Kidney-sparing approach for selected localized high-risk upper tract urothelial carcinoma: A pilot study combining endoscopic thulium laser ablation with perioperative disitamab vedotin and immune checkpoint inhibitors.6 d0 e2 W- W0 u) V
18.Comprehensive modalities of kidney-sparing treatment in a carefully selected cohort of localized high-risk upper tract urothelial carcinoma: A potential paradigm shift.
6 T4 L& u' f7 b8 L$ K Y19.Efficacy of systemic treatments for advanced non-clear cell renal cell carcinoma: A single-arm systematic review and meta-analysis.
$ r% f ~1 q3 e X& T0 g20.The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer.
7 m9 x r) X3 B" d! O5 f5 {( {9 g4 Z3 ?21.Global spatiotemporal trends in prostate cancer burden and its socioeconomic disparities: An observational study from 1990 to 2021.3 U4 x; e# l. Y( G1 H( s
22.Optimizing the strategies to perform prostate biopsy in MRI-positive patients: A systematic review and network meta-analysis.! f# g' q9 }/ I7 X. G
23.Assessment of the proficiency of ChatGPT-4o in an image-based robot-assisted radical prostatectomy scenario.+ ~" U2 X3 \3 e/ e& | M
24.The prognostic significance of circulating tumor DNA in prostate cancer: A systematic review and meta-analysis.7 s- M) E' E; U& P$ c" S1 j
25.Global and regional burden of kidney cancer: Analysis and future predictions based on GBD data from 1990 to 2021.4 }+ ~; f9 z4 t4 S5 H' a& T
|
|
发表于 2025-1-9 15:59:44
发表于 2025-1-9 17:01:32
看年内重离子质子医院投运后，能否发起追赶
